Brainstorm Cell Therapeutics may be sliding down financialy. It has an above-average odds of going through some form of financial crisis next quarter. As of now, Brainstorm Cell's Common Stock Total Equity is increasing as compared to previous years. The Brainstorm Cell's current Common Stock Shares Outstanding is estimated to increase to about 52 M, while Short and Long Term Debt Total is projected to decrease to under 734.2 K. Key indicators impacting Brainstorm Cell's financial strength include:
Investors should never underestimate Brainstorm Cell's ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to monitor Brainstorm Cell's cash flow, debt, and profitability to make informed and accurate decisions about investing in Brainstorm Cell Therapeutics.
Net Income
(14.7 Million)
Brainstorm
Select Account or Indicator
Market Cap
Enterprise Value
Price To Sales Ratio
Ptb Ratio
Book Value Per Share
Free Cash Flow Yield
Operating Cash Flow Per Share
Average Payables
Capex To Depreciation
Pb Ratio
Ev To Sales
Free Cash Flow Per Share
Roic
Net Income Per Share
Payables Turnover
Sales General And Administrative To Revenue
Cash Per Share
Pocfratio
Interest Coverage
Capex To Operating Cash Flow
Pfcf Ratio
Days Payables Outstanding
Income Quality
Roe
Ev To Operating Cash Flow
Pe Ratio
Return On Tangible Assets
Ev To Free Cash Flow
Earnings Yield
Intangibles To Total Assets
Net Debt To E B I T D A
Current Ratio
Tangible Book Value Per Share
Shareholders Equity Per Share
Debt To Equity
Capex Per Share
Graham Net Net
Average Receivables
Revenue Per Share
Interest Debt Per Share
Debt To Assets
Enterprise Value Over E B I T D A
Short Term Coverage Ratios
Price Earnings Ratio
Price Book Value Ratio
Price Earnings To Growth Ratio
Days Of Payables Outstanding
Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio
Pretax Profit Margin
Ebt Per Ebit
Operating Profit Margin
Effective Tax Rate
Company Equity Multiplier
Long Term Debt To Capitalization
Total Debt To Capitalization
Return On Capital Employed
Debt Equity Ratio
Ebit Per Revenue
Quick Ratio
Dividend Paid And Capex Coverage Ratio
Net Income Per E B T
Cash Ratio
Cash Conversion Cycle
Operating Cash Flow Sales Ratio
Free Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage Ratios
Price To Book Ratio
Capital Expenditure Coverage Ratio
Price Cash Flow Ratio
Enterprise Value Multiple
Debt Ratio
Cash Flow To Debt Ratio
Price Sales Ratio
Return On Assets
Asset Turnover
Net Profit Margin
Gross Profit Margin
Price Fair Value
Return On Equity
Change In Cash
Free Cash Flow
Change In Working Capital
Begin Period Cash Flow
Other Cashflows From Financing Activities
Depreciation
Other Non Cash Items
Capital Expenditures
Total Cash From Operating Activities
Net Income
Total Cash From Financing Activities
End Period Cash Flow
Sale Purchase Of Stock
Change To Inventory
Stock Based Compensation
Change To Account Receivables
Total Cashflows From Investing Activities
Other Cashflows From Investing Activities
Investments
Change Receivables
Cash And Cash Equivalents Changes
Change To Netincome
Change To Liabilities
Cash Flows Other Operating
Change To Operating Activities
Issuance Of Capital Stock
Total Assets
Short Long Term Debt Total
Other Current Liab
Total Current Liabilities
Total Stockholder Equity
Net Debt
Retained Earnings
Cash
Non Current Assets Total
Cash And Short Term Investments
Common Stock Total Equity
Common Stock Shares Outstanding
Liabilities And Stockholders Equity
Non Current Liabilities Total
Other Current Assets
Other Stockholder Equity
Total Liab
Total Current Assets
Short Term Debt
Intangible Assets
Common Stock
Property Plant And Equipment Net
Property Plant And Equipment Gross
Accumulated Other Comprehensive Income
Current Deferred Revenue
Accounts Payable
Non Currrent Assets Other
Net Receivables
Other Liab
Other Assets
Property Plant Equipment
Net Tangible Assets
Retained Earnings Total Equity
Short Term Investments
Capital Surpluse
Long Term Investments
Non Current Liabilities Other
Net Invested Capital
Net Working Capital
Capital Lease Obligations
Depreciation And Amortization
Interest Expense
Selling General Administrative
Gross Profit
Other Operating Expenses
Operating Income
Ebit
Ebitda
Cost Of Revenue
Total Operating Expenses
Income Before Tax
Total Other Income Expense Net
Income Tax Expense
Research Development
Selling And Marketing Expenses
Net Income From Continuing Ops
Net Income Applicable To Common Shares
Interest Income
Net Interest Income
Reconciled Depreciation
Probability Of Bankruptcy
Understanding current and past Brainstorm Cell Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Brainstorm Cell's financial statements are interrelated, with each one affecting the others. For example, an increase in Brainstorm Cell's assets may result in an increase in income on the income statement.
Brainstorm Cell competes with Protalix Biotherapeutics, Corvus Pharmaceuticals, Aldeyra, Checkpoint Therapeutics, and Werewolf Therapeutics. Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York. Brainstorm Cell operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 43 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
Comparative valuation techniques use various fundamental indicators to help in determining Brainstorm Cell's current stock value. Our valuation model uses many indicators to compare Brainstorm Cell value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Brainstorm Cell competition to find correlations between indicators driving Brainstorm Cell's intrinsic value. More Info.
Brainstorm Cell Therapeutics is rated below average in return on equity category among its peers. It also is rated below average in return on asset category among its peers . As of now, Brainstorm Cell's Return On Equity is increasing as compared to previous years. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Brainstorm Cell's earnings, one of the primary drivers of an investment's value.
Brainstorm Cell Ther Systematic Risk
Brainstorm Cell's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Brainstorm Cell volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty with a total number of output elements of fourty-one. The Beta measures systematic risk based on how returns on Brainstorm Cell Ther correlated with the market. If Beta is less than 0 Brainstorm Cell generally moves in the opposite direction as compared to the market. If Brainstorm Cell Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Brainstorm Cell Ther is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Brainstorm Cell is generally in the same direction as the market. If Beta > 1 Brainstorm Cell moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Brainstorm Cell Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Brainstorm Cell's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Brainstorm Cell growth as a starting point in their analysis.
Along with financial statement analysis, the daily predictive indicators of Brainstorm Cell help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Brainstorm Cell Therapeutics. We use our internally-developed statistical techniques to arrive at the intrinsic value of Brainstorm Cell Therapeutics based on widely used predictive technical indicators. In general, we focus on analyzing Brainstorm Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Brainstorm Cell's daily price indicators and compare them against related drivers.
When running Brainstorm Cell's price analysis, check to measure Brainstorm Cell's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Brainstorm Cell is operating at the current time. Most of Brainstorm Cell's value examination focuses on studying past and present price action to predict the probability of Brainstorm Cell's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Brainstorm Cell's price. Additionally, you may evaluate how the addition of Brainstorm Cell to your portfolios can decrease your overall portfolio volatility.